CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced data today from ...
Please provide your email address to receive an email when new articles are posted on . Valoctocogene roxaparvovec induced endogenous factor VIII production and significantly reduced bleeding and ...
The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia ...
CAAR-T therapy may eliminate FVIII inhibitors in hemophilia A, potentially improving replacement treatment effectiveness, a study shows.
ABOUT 5 per cent of haemophilic patients develop in their blood an inhibitor to factor VIII. The most likely explanation is that this is due to an immunological response to antihaemophilic factor of ...
SOUTH SAN FRANCISCO, Calif., December 08, 2025--(BUSINESS WIRE)--SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic ...
Hemophilia A patients manage the chronic disorder with infusions administered as frequently as every two to three days. The FDA has approved a Sanofi drug designed to last longer in the body, giving ...
Researchers from the Centenary Institute have uncovered a reason why some people with hemophilia A develop resistance to their critical treatment, paving the way for the development of more effective ...
Early initiation of prophylaxis regimens and joint status monitoring over time are the most relevant aspects of evaluating treatment efficacy in this patient population, study authors concluded. For ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results